Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602

Acta Oncol. 2012 Sep;51(7):944-7. doi: 10.3109/0284186X.2011.640347. Epub 2011 Dec 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / immunology
  • Dexamethasone / administration & dosage
  • Drug Eruptions / diagnosis
  • Drug Eruptions / etiology*
  • Drug Eruptions / immunology
  • Female
  • HLA-A Antigens / analysis
  • HLA-B Antigens / analysis
  • HLA-C Antigens / analysis
  • HLA-DQ beta-Chains / genetics*
  • HLA-DRB1 Chains / genetics*
  • Humans
  • Italy
  • Lenalidomide
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / immunology*
  • Prednisolone / administration & dosage
  • Severity of Illness Index
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thalidomide / immunology
  • White People / genetics

Substances

  • Antineoplastic Agents
  • HLA-A Antigens
  • HLA-B Antigens
  • HLA-C Antigens
  • HLA-DQ beta-Chains
  • HLA-DQB1 antigen
  • HLA-DRB1 Chains
  • HLA-DRB1*15:01 antigen
  • Thalidomide
  • Dexamethasone
  • Prednisolone
  • Lenalidomide